2000
DOI: 10.1002/1099-1557(200009/10)9:5<441::aid-pds491>3.0.co;2-b
|View full text |Cite
|
Sign up to set email alerts
|

Current Awareness

Abstract: In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 19 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2000
2000
2000
2000

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 387 publications
0
1
0
Order By: Relevance
“…Often hematological and other relevant laboratories are unremarkable; however, prolonged bleeding time of 12.5 min (Calhoun and Calhoun 1996), mildly decreased platelet counts of 131,000/mm3, and 142,000/mm3, respectively (Aranth and Lingberg 1992;Leung 1996) 35 1997) have been described. In a small study by Alderman and colleagues (1996), seven patients on fluoxetine (20 mg/day) and one patient on paroxetine (20 mg/day) had no abnormalities in platelet aggregation, hematopoiesis, or coagulation profiles within 4 weeks of initiation of SSRI trial.…”
Section: Introductionmentioning
confidence: 99%
“…Often hematological and other relevant laboratories are unremarkable; however, prolonged bleeding time of 12.5 min (Calhoun and Calhoun 1996), mildly decreased platelet counts of 131,000/mm3, and 142,000/mm3, respectively (Aranth and Lingberg 1992;Leung 1996) 35 1997) have been described. In a small study by Alderman and colleagues (1996), seven patients on fluoxetine (20 mg/day) and one patient on paroxetine (20 mg/day) had no abnormalities in platelet aggregation, hematopoiesis, or coagulation profiles within 4 weeks of initiation of SSRI trial.…”
Section: Introductionmentioning
confidence: 99%